Why is "Study 329" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-27 04:04:24
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Judge tosses lawsuit over controversial Paxil ‘Study 329’ - Retraction Watch
-
Controversial Paxil “Study 329” Earns Expression of Concern After Critic Sues Publisher - Mad In America
-
Controversial Paxil “Study 329” earns expression of concern after critic sues publisher - Retraction Watch
-
Infamous antidepressant drug trial back in spotlight after journal sued - CTV News
-
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence - The BMJ
-
A major new study about a blockbuster antidepressant. - Psychology Today
-
Antidepressant trial’s upended results show need for sharing all data - The Conversation
-
Controversial Paxil paper still under fire 13 years later - The Brown Daily Herald
-
The Troubled Life of Study 329: Consequences of Failure to Retract - Mad In America
-
Is Paxil (Paroxetine) Unsafe for Teens? - The People's Pharmacy
-
How researchers dupe the public with a sneaky practice called “outcome switching” - vox.com
-
New look at antidepressant suicide risks from infamous trial - New Scientist
-
Analysis of paroxetine trial sparks debate over access to trial data - The Pharmaceutical Journal
-
The BMJ Today: GSK’s Study 329, BMJ Confidential, and facial nerve palsy - BMJ Blogs
-
Study 329: The Timelines - Mad In America
-
What Happened to those Who Were Suicidal in Study 329? And to the Learned Intermediaries? - Mad In America
-
Study 329: Conflicts of Interest - Mad In America
-
Study 329: The Data Wars Cross the Rubicon - Mad In America
-
Study 329 Trick, Treat or Treximet - Mad In America
-
Jon Jureidini - The Medical Journal of Australia
-
Seroxat study under-reported harmful effects on young people, say scientists - The Guardian
-
Reanalysis finds popular antidepressant ineffective, unsafe for teens - CBC
-
Popular antidepressant Paxil (paroxetine) not safe or effective for teens, study finds - CBS News
-
Drug company experts advised staff to withhold data about SSRI use in children - CMAJ
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.